Little patients, losing patience: Pediatric cancer drug development

Molecular Cancer Therapeutics

Volumn 5, Issue 8, 2006, Pages 1905-1908

  Boklan, Jessica ^a  

^a PHOENIX CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CLOFARABINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BUDGET; CANCER MORTALITY; CANCER RESEARCH; CHILD; CHILD BEHAVIOR; CHILDHOOD CANCER; CLINICAL STUDY; CLINICAL TRIAL; DRUG APPROVAL; DRUG FORMULATION; DRUG RESEARCH; DRUG RESPONSE; EDITORIAL; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HUMAN; MEDICAL ETHICS; MEDICAL SPECIALIST; MYELODYSPLASTIC SYNDROME; PATIENCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; ETHICS, MEDICAL; HUMANS; NEOPLASMS; PARENTS; UNITED STATES;

EID: 33748349687     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0179     Document Type: Editorial

References (18)

1. Hirschfeld S, Ho PTC, Smith M, Pazdur R. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. J Clin Oncol 2003;21:1066-73.
2. Department of Health and Human Services, U.S. Food and Drug Administration. Patient access to new therapeutic agents for pediatric cancer, December 2003: report to Congress. Washington (DC): Department of Health and Human Services, U.S. Food and Drug Administration; 2003.
3. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
4. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22: 151-85.
5. Pharmaceutical Research and Manufacturers of America (PhRMA). Pharmaceutical industry profile, 2004. Washington (DC): Pharmaceutical Research and Manufacturers of America; 2004.
6. Miller RW, Young JL, Jr., Novakovic B. Childhood cancer. Cancer 1995;75:395-405.
7. Meadows M. Drug research and children. U.S. Food and Drug Administration. FDA consumer magazine. 2003 Jan-Feb. Available from: http://www.fda.gov/fdac/features/2003/103_drugs.html.
8. Biotechnology Industry Organization. History of pediatric studies, rule, legislation, and litigation. Available from: http://www.bio.org/reg/ action/pedhist.asp?P=yes.
9. Food and Drug Administration. Pediatric exclusivity statistics as of February 28, 2006. Available from: http://www.fda.gov/cder/pediatric/ wrstats.htm.
10. National Cancer Institute. Cancer research funding. National Cancer Institute Fact Sheet; 2005. Available from: http://www.cancer.gov/ cancertopics/factsheet/NCI/research-funding.
11. National Cancer Institute. National Cancer Institute research on childhood cancers: Fact Sheet. National Cancer Institute Fact Sheet; 2005. Available from: http://www.cancer.gov/cancertopies/factsheet/ Sites-Types/childhood.
12. National Cancer Institute. Survivors of childhood cancer and chronic illness; 2006. Available from: http://www.cancer.gov/cancertopics/coping/ childhood-cancer-survivor-study.
13. National Cancer Institute. Late effects of treatment for childhood cancer; 2006. Available from: http://www.cancer.gov/cancertopics/pdq/ treatment/lateeffects/HealthProfessional/page2.
14. Conquer Childhood Cancer Act, S. 2393/H.R. 4927 (2006).
15. Issa J-P. Progress in the treatment of myelodysplastic syndromes: update on decitabine clinical trials. 47th American Society of Hematology Annual Meeting Corporate Friday Symposium, Atlanta; 2005 Dec 9.
16. Assent Task Force, Children's Oncology Group. Decision-making about research participation. Available from: http://www.childrensoncologygroup.org/_files/COGAssentGuidelines.pdf.
17. Ries LAG, Eisner MP, Kosary CL, et al., editors. Surveillance Epidemiology and End Results (SEER) cancer statistics review, 1975-2002, National Cancer Institute, Bethesda, MD. Available from: http://seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, posted to the SEER Web site 2005.
18. Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 2002;20:2109-17.